[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_ac699874-3f57-4b91-8cdf-ec8aaae2b5f0":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:ac699874-3f57-4b91-8cdf-ec8aaae2b5f0,\"}":51},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":21,"indexDatabases":22,"url":18,"thumbnailPath":18,"statistic":23,"gsStatistic":18,"type":50,"analyzePriority":18},"ac699874-3f57-4b91-8cdf-ec8aaae2b5f0","2024-04-18T01:40:40.456+00:00","2024-09-01T05:57:04.732+00:00",[],"Medisch-Farmaceutische-Mededelingen",{"issn":12,"title":14},{"VOID":13},"18765971",{"VOID":15},"Medisch-Farmaceutische Mededelingen","PUBLISHER","PENDING",null,0,[],[],[],{"impactFactor":19,"impactFactorByYear":24,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":26,"totalCitation":38,"totalCitationByYear":39,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":46,"hindexLast5Year":40,"hindex":40},{},1758,{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},129,110,148,117,122,166,153,149,123,128,133,20,{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},3,4,2,7,1,0.01,{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},0.03,0.02,0.05,"JOURNAL",{"meta":52,"data":54},{"total":53},"1758",[55,119,165,208,253,298,343,386,432,487],{"id":56,"createTime":57,"updateTime":58,"relativeEntities":59,"slug":60,"properties":61,"entityType":72,"verifyStatus":17,"verifyTime":58,"verifyNote":73,"syncStatus":17,"languages":74,"translateLanguages":18,"viewCount":19,"primaryUrl":76,"fullTextUrl":18,"authors":77,"publicationType":87,"publisherRelationship":88,"citationCount":19,"citationInfo":109,"publishDate":111,"publishYear":112,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":113,"isForceReanalyzing":118},"caf86c82-a8ee-40cd-9e97-6cd61375ea95","2024-04-19T12:31:15.795+00:00","2025-01-19T23:59:13.514+00:00",[],"Geneesmiddelen-in-het-drinkwater",{"mag":62,"keywords":64,"openalex":65,"abstract":67,"title":68,"doi":70},{"VOID":63},"2076485871",{},{"VOID":66},"W2076485871",{},{"NL":69},"Geneesmiddelen in het drinkwater",{"VOID":71},"10.1007\u002Fbf03079930","PUBLICATION","Author affiliation is blank",[75],"NL","http:\u002F\u002Flink.springer.com\u002F10.1007\u002FBF03079930",[78],{"id":79,"sortIndex":19,"researcher":18,"roles":80,"affiliations":81,"properties":82},"f7168c99-5d79-4a42-8f20-e2e91b213c15",[],[],{"openalex":83,"title":85},{"VOID":84},"A5033160146",{"EN":86},"P. J. M. M. Toll","ARTICLE",{"url":18,"publisher":89,"properties":102},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":90,"slug":10,"properties":91,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":94,"manageAffiliations":95,"indexDatabases":96,"url":18,"thumbnailPath":18,"statistic":97,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":92,"title":93},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":98,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":99,"totalCitation":38,"totalCitationByYear":100,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":101,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":103,"pages":105,"issue":107},{"VOID":104},"47",{"VOID":106},"60-60",{"VOID":108},"4",{"total":19,"publishYear":18,"statisticByYear":110},{},"2009-04-01",2009,[114],{"id":18,"text":115,"url":18,"identifiers":116},"Watts G. How clean is your water? BMJ 2008;337:80-2.",{"doi":117},"10.1136\u002Fbmj.a237",false,{"id":120,"createTime":121,"updateTime":122,"relativeEntities":123,"slug":124,"properties":125,"entityType":72,"verifyStatus":17,"verifyTime":122,"verifyNote":73,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":134,"fullTextUrl":18,"authors":135,"publicationType":87,"publisherRelationship":144,"citationCount":18,"citationInfo":18,"publishDate":163,"publishYear":164,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":118},"61bd805b-6be6-4482-af37-323bea980b13","2024-01-25T02:42:43.210+00:00","2025-02-16T23:57:56.948+00:00",[],"Is-amiodaron-wel-a-veilig-bij-hartfalen-",{"references":126,"abstract":128,"title":130,"doi":132},{"VOID":127},"Coceani M, Mariotti R. Is amiodaron safe in heart failure? Br Med J 2006; 332: 317-19.",{"EN":129},"Hartfalen (HF) is een complex klinisch syndroom dat kan leiden tot plotse dood. Het antiaritmicum amiodaron zou dit risico verkleinen. Er zijn diverse, niet altijd vergelijkbare, onderzoeken gedaan met amiodaron en de resultaten spreken elkaar tegen. Amiodaron beïnvloedt de ion-kanalen van natrium, kalium en calcium en tevens alfa- en bèta-adrenerge receptoren. Dit leidt tot diverse elektrofysiologische effecten met inbegrip van vermindering van de geleidingssnelheid van de hartspier. Amiodaron hoopt zich op in hartspierweefsel, waardoor bradyaritmieën kunnen ontstaan, wat weer kan leiden tot plotse dood bij gevorderd hartfalen. Ook is amiodaron in verband gebracht met tachyaritmieën, zoals torsades de pointes die optreden in geval van laag kalium en magnesium.",{"EN":131},"Is amiodaron wel a veilig bij hartfalen?",{"VOID":133},"10.1007\u002FBF03058789","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002FBF03058789",[136],{"id":137,"sortIndex":19,"researcher":18,"roles":138,"affiliations":140,"properties":141},"23f433d7-414d-4b77-af79-17ca6a82fc6a",[139],"AUTHOR",[],{"title":142},{"VI":143},"E. van der Does",{"url":134,"publisher":145,"properties":158},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":146,"slug":10,"properties":147,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":150,"manageAffiliations":151,"indexDatabases":152,"url":18,"thumbnailPath":18,"statistic":153,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":148,"title":149},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":154,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":155,"totalCitation":38,"totalCitationByYear":156,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":157,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":159,"pages":161},{"VOID":160},"44",{"VOID":162},"149-149","2006-06-01",2006,{"id":166,"createTime":167,"updateTime":167,"relativeEntities":168,"slug":18,"properties":169,"entityType":72,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":178,"fullTextUrl":18,"authors":179,"publicationType":87,"publisherRelationship":187,"citationCount":18,"citationInfo":18,"publishDate":206,"publishYear":207,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":118},"21026c4b-09ae-4c5b-b647-a7d545c17fef","2024-02-08T23:56:34.474+00:00",[],{"references":170,"abstract":172,"title":174,"doi":176},{"VOID":171},"St. Elair EW, Heijde DMFM van der, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004;50:3432-43.",{"EN":173},"Reumatoïde artritis (RA) is een chronische, inflammatoire polyartritis, met een progressief verloop, die leidt tot gewrichtsdestructie en invaliditeit. In de doorgaans korte periode tussen het begin van de gewrichtsontstekingen en de ontwikkeling van boterosies speelt een toegenomen expressie van tumornecrosefactor-alfa (TNF-α) een rol. De effectiviteit van TNF-α-blokkerende middelen, zoals infliximab, is aangetoond bij patiënten met RA. Het is echter onduidelijk welke effectiviteit combinatietherapie van methotrexaat (MTX) en een TNF-α-blokke-rend middel bezit.",{"EN":175},"Combinatietherapie in een vroeg stadium van reumatoïde artritis",{"VOID":177},"10.1007\u002FBF03058542","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002FBF03058542",[180],{"id":181,"sortIndex":19,"researcher":18,"roles":182,"affiliations":183,"properties":184},"3857d6ba-3aee-4398-82b3-b51a07c4e67b",[139],[],{"title":185},{"VI":186},"A. Vermes",{"url":178,"publisher":188,"properties":201},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":189,"slug":10,"properties":190,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":193,"manageAffiliations":194,"indexDatabases":195,"url":18,"thumbnailPath":18,"statistic":196,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":191,"title":192},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":197,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":198,"totalCitation":38,"totalCitationByYear":199,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":200,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":202,"pages":204},{"VOID":203},"43",{"VOID":205},"43-43","2005-02-01",2005,{"id":209,"createTime":210,"updateTime":211,"relativeEntities":212,"slug":213,"properties":214,"entityType":72,"verifyStatus":17,"verifyTime":211,"verifyNote":73,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":223,"fullTextUrl":18,"authors":224,"publicationType":87,"publisherRelationship":232,"citationCount":18,"citationInfo":18,"publishDate":251,"publishYear":252,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":118},"ea8b98f9-e798-4d8b-a9d5-f1bff2f1d87d","2023-12-14T02:43:38.162+00:00","2025-02-07T23:56:05.150+00:00",[],"Postco%C3%AFtale-contraceptie",{"references":215,"abstract":217,"title":219,"doi":221},{"VOID":216},"Ellertson Ch et al. OBSTET GYNECOL 2003; 101: 1160-7.\nJackson R et al. OBSTET GYNECOL 2003; 102: 8-16.\nRaine T. OBSTET GYNECOL 2003; 102: 1-2.\nRaymond E et al. OBSTET GYNECOL 2003; 102: 17-23.",{"EN":218},"Er blijven publicaties komen rond de ‘morning after’ pil (mfm 2003; 41: 29). Zo verscheen een onderzoek naar variaties op het Yuzperegiem en werden vragen rond OTC-gebruik (‘over the counter’: zonder recept verkrijgbaar, ook bij de drogist) beantwoord.",{"EN":220},"Postcoïtale contraceptie",{"VOID":222},"10.1007\u002FBF03058286","http:\u002F\u002Flink.springer.com\u002F10.1007\u002FBF03058286",[225],{"id":226,"sortIndex":19,"researcher":18,"roles":227,"affiliations":228,"properties":229},"16f18389-b378-456b-b7d0-8b7d5235c6c1",[139],[],{"title":230},{"VI":231},"   ",{"url":223,"publisher":233,"properties":246},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":234,"slug":10,"properties":235,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":238,"manageAffiliations":239,"indexDatabases":240,"url":18,"thumbnailPath":18,"statistic":241,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":236,"title":237},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":242,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":243,"totalCitation":38,"totalCitationByYear":244,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":245,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":247,"pages":249},{"VOID":248},"41",{"VOID":250},"302-303","2003-10-01",2003,{"id":254,"createTime":255,"updateTime":256,"relativeEntities":257,"slug":258,"properties":259,"entityType":72,"verifyStatus":17,"verifyTime":268,"verifyNote":73,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":269,"fullTextUrl":18,"authors":270,"publicationType":87,"publisherRelationship":277,"citationCount":18,"citationInfo":18,"publishDate":296,"publishYear":297,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":118},"236ae4fa-c68c-48e7-b258-546d0542d99e","2024-01-10T19:07:06.163+00:00","2025-02-21T23:55:19.369+00:00",[],"Relatie-H-pylori-maagkankerHelicobacter-pylori-infectie-en-maagkankermaagkanker",{"references":260,"abstract":262,"title":264,"doi":266},{"VOID":261},"Watanabe T et al. Gastroenterology 1998 ; 115 : 642-8.\nEditorial. Gastroenterology 1998; 115: 780-2.",{"EN":263},"Hoewel epidemiologische onderzoeken sterke aanwijzingen hebben opgeleverd dat een infectie met Helicobacter pylori een cruciale rol speelt bij het ontstaan van maagkanker en enig geduld en observaties in de tijd deze aanwijzingen vrijwel zeker zullen versterken, meenden Japanse onderzoekers dat toch ‘meer direct’ te moeten bewijzen. Daartoe infecteerden zij in het zoveelste diermodel (specifieke pathogeenvrije Mongoolse mannelijke) woestijnratten van vijf weken oud met Helicobacter pylori via de orale weg en vervolgden de dieren gedurende 62 weken. Bij 26 weken waren er ulcera aantoonbaar, in een actieve chronische gastritis, alsmede metaplasie. Bij afloop van het onderzoek had 37% van de geïnfecteerde dieren adenocarcinoom in de pylorisstreek ontwikkeld.",{"EN":265},"Relatie H. pylori, maagkankerHelicobacter pylori-infectie en maagkankermaagkanker",{"VOID":267},"10.1007\u002FBF03057560","2025-02-21T23:55:19.368+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002FBF03057560",[271],{"id":272,"sortIndex":19,"researcher":18,"roles":273,"affiliations":274,"properties":275},"e1f09153-abe7-43c7-b79e-c786d82eb379",[139],[],{"title":276},{"VI":231},{"url":269,"publisher":278,"properties":291},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":279,"slug":10,"properties":280,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":283,"manageAffiliations":284,"indexDatabases":285,"url":18,"thumbnailPath":18,"statistic":286,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":281,"title":282},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":287,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":288,"totalCitation":38,"totalCitationByYear":289,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":290,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":292,"pages":294},{"VOID":293},"38",{"VOID":295},"130-130","2000-06-01",2000,{"id":299,"createTime":300,"updateTime":301,"relativeEntities":302,"slug":303,"properties":304,"entityType":72,"verifyStatus":17,"verifyTime":301,"verifyNote":73,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":313,"fullTextUrl":18,"authors":314,"publicationType":87,"publisherRelationship":322,"citationCount":18,"citationInfo":18,"publishDate":341,"publishYear":342,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":118},"9743d1bf-1805-4945-90c2-099e0731e9e5","2024-01-29T03:51:42.520+00:00","2024-12-27T23:55:05.489+00:00",[],"Finasteride-en-mammacarcinoom-bij-mannen",{"references":305,"abstract":307,"title":309,"doi":311},{"VOID":306},"Wysowski DK, Farinas E. Finasteride in benign prostatic hyperplasia [letter]. N Engl J Med 2004;350:1359.\nVerhamme KMC, Bosch RJLH, Sturkenboom MCJM. Finasteride in benign prostatic hyperplasia [letter]. N Engl J Med 2004;350:1359-60.\nRoehrborn C. Finasteride in benign prostatic hyperplasia [author's reply]. N Engl J Med 2004;350:1360-1.",{"EN":308},"Finasteride (Proscar) is een bekend middel tegen benigne) prostaathypertrofie (BPH). Het remt de omzetting van testosteron tot het potentere dihydrotestosteron. De meest vervelende bijwerkingen zijn verlaging van het libido en impotentie en natuurlijk de bekende gynaecomastie. Verontrustend is de bevinding (in het grote klinische onderzoek met de codenaam MTOPS [Medical Therapy of Prostatic Symptoms], 2003) dat gebruik op lange termijn (gemiddeld 22 maanden) in sporadische gevallen intraductaal mammacarcinoom lijkt te veroorzaken.",{"EN":310},"Finasteride en mammacarcinoom bij mannen",{"VOID":312},"10.1007\u002FBF03058447","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002FBF03058447",[315],{"id":316,"sortIndex":19,"researcher":18,"roles":317,"affiliations":318,"properties":319},"69f1726f-0960-46c0-ba7d-fc34e7779392",[139],[],{"title":320},{"VI":321},"H. R. de Vries",{"url":313,"publisher":323,"properties":336},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":324,"slug":10,"properties":325,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":328,"manageAffiliations":329,"indexDatabases":330,"url":18,"thumbnailPath":18,"statistic":331,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":326,"title":327},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":332,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":333,"totalCitation":38,"totalCitationByYear":334,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":335,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":337,"pages":339},{"VOID":338},"42",{"VOID":340},"225-225","2004-08-01",2004,{"id":344,"createTime":345,"updateTime":346,"relativeEntities":347,"slug":348,"properties":349,"entityType":72,"verifyStatus":17,"verifyTime":346,"verifyNote":73,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":358,"fullTextUrl":18,"authors":359,"publicationType":87,"publisherRelationship":367,"citationCount":18,"citationInfo":18,"publishDate":385,"publishYear":342,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":118},"7cd972bc-6322-4d0c-975d-d77a2b41be89","2024-02-23T04:56:48.634+00:00","2025-01-07T23:53:45.661+00:00",[],"Magnesium-verbetert-insulinegevoeligheid-en-metabole-controle-bij-diabetes",{"references":350,"abstract":352,"title":354,"doi":356},{"VOID":351},"Rodriguez-Morán M, Guerrero-Romero F.Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects. Diabetes Care 2003; 26:1147-52.",{"EN":353},"Hoewel in de kliniek doorgaans weinig aandacht wordt besteed aan de magnesiumhuishouding is daar wel alle aanleiding toe: 10 tot 65% van de‘gewone’ opgenomen patiënten op de intensive care heeft een tekort aan magnesium.",{"EN":355},"Magnesium verbetert insulinegevoeligheid en metabole controle bij diabetes",{"VOID":357},"10.1007\u002FBF03058328","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002FBF03058328",[360],{"id":361,"sortIndex":19,"researcher":18,"roles":362,"affiliations":363,"properties":364},"1a140403-7740-49de-ab60-b39467d72370",[139],[],{"title":365},{"VI":366},"A. C. M. Vingerhoeds",{"url":358,"publisher":368,"properties":381},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":369,"slug":10,"properties":370,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":373,"manageAffiliations":374,"indexDatabases":375,"url":18,"thumbnailPath":18,"statistic":376,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":371,"title":372},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":377,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":378,"totalCitation":38,"totalCitationByYear":379,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":380,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":382,"pages":383},{"VOID":338},{"VOID":384},"52-53","2004-02-01",{"id":387,"createTime":388,"updateTime":389,"relativeEntities":390,"slug":391,"properties":392,"entityType":72,"verifyStatus":17,"verifyTime":401,"verifyNote":73,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":402,"fullTextUrl":18,"authors":403,"publicationType":87,"publisherRelationship":411,"citationCount":18,"citationInfo":18,"publishDate":430,"publishYear":431,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":118},"77f8de40-7b5e-47d5-9dec-3ff62be95c93","2024-01-25T01:40:15.894+00:00","2025-01-18T23:53:37.745+00:00",[],"Invloed-van-nierfalen-op-de-farmacokinetiek-van-bupropion-en-zijn-metabolieten",{"references":393,"abstract":395,"title":397,"doi":399},{"VOID":394},"Turpeinen M, Koivuviita N, Tolonen A, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol 2007; 64: 165-73.",{"EN":396},"Bupropion – een hulpmiddel bij stoppen met roken en tevens antidepressivum (voor het laatste is het niet in Nederland geregistreerd. Ref.) – wordt voornamelijk in de lever geklaard. Voor een belangrijk deel wordt het gemetaboliseerd tot de actieve metaboliet hydroxybupropion. Het betrokken leverenzym is cytochroom P450 2B6 (CYP2B6). De hydroxylering van bupropion is aldus een maat voor de activiteit van het CYP2B6. Nu is uit verschillende onderzoeken gebleken dat het metabolisme in de lever beïnvloed kan worden door nierfalen.Voor CYP2C9 en CYP3A4 is dat al aangetoond. Het is echter nog onduidelijk of ook de activiteit van CYP2B6 wordt beïnvloed. Bupropion kan convulsies en andere toxische effecten op het centrale zenuwstelsel veroorzaken bij hoge plasmaconcentraties. Van belang is om te weten of bij nierfalen de dosis moet worden aangepast. Turpeinen et al. onderzochten de farmacokinetiek van bupropion en zijn metabolieten en de CYP2B6-activiteit in 17 gezonde niet-rokers en 10 niet-rokers met stabiel nierfalen. De gezonde proefpersonen gebruikten geen orale medicatie en de proefpersonen met nierfalen gebruikten geen bekende remmers of inductoren van CYP2B6. De plasmaconcentraties van bupropion, hydroxybupropion en hydrobupropion werden gedurende 72 uur bepaald na een eenmalig orale dosis van 150 mg bupropion.Vervolgens werden de volgende farmacokinetische parameters berekend: maximale plasmaconcentratie (Cmax), tijd tot Cmax (tmax), halfwaardetijd (t1⁄2), area under the curve (AUC) en orale klaring (CL\u002FF).Tevens werd de genotypering van CYP2B6 SNPs 1459 C>T en 516 G>T en SNP 785 A>G bepaald.",{"EN":398},"Invloed van nierfalen op de farmacokinetiek van bupropion en zijn metabolieten",{"VOID":400},"10.1007\u002FBF03059091","2025-01-18T23:53:37.744+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002FBF03059091",[404],{"id":405,"sortIndex":19,"researcher":18,"roles":406,"affiliations":407,"properties":408},"a148a9d7-c1e0-4cd3-b541-0829eddacad0",[139],[],{"title":409},{"VI":410},"H. J. M. G. Nelissen-Vrancken",{"url":402,"publisher":412,"properties":425},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":413,"slug":10,"properties":414,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":417,"manageAffiliations":418,"indexDatabases":419,"url":18,"thumbnailPath":18,"statistic":420,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":415,"title":416},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":421,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":422,"totalCitation":38,"totalCitationByYear":423,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":424,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":426,"pages":428},{"VOID":427},"45",{"VOID":429},"307-308","2007-10-01",2007,{"id":433,"createTime":434,"updateTime":435,"relativeEntities":436,"slug":437,"properties":438,"entityType":72,"verifyStatus":17,"verifyTime":435,"verifyNote":73,"syncStatus":17,"languages":449,"translateLanguages":18,"viewCount":19,"primaryUrl":450,"fullTextUrl":18,"authors":451,"publicationType":87,"publisherRelationship":461,"citationCount":19,"citationInfo":475,"publishDate":477,"publishYear":112,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":478,"isForceReanalyzing":118},"61f6f2f6-3b16-49b5-9d4e-1bfbd7d8c805","2024-04-11T21:44:12.928+00:00","2025-01-17T23:53:35.068+00:00",[],"Thuisbehandeling-van-kinderen-met-een-ernstige-pneumonie-met-een-korte-kuur-van-een-hoge-dosering-amoxicilline-een-gerandomiseerd-equivalentieonderzoek",{"mag":439,"keywords":441,"openalex":442,"abstract":444,"title":445,"doi":447},{"VOID":440},"2049769196",{},{"VOID":443},"W2049769196",{},{"NL":446},"Thuisbehandeling van kinderen met een ernstige pneumonie met een korte kuur van een hoge dosering amoxicilline: een gerandomiseerd equivalentieonderzoek",{"VOID":448},"10.1007\u002Fbf03079986",[75],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002FBF03079986",[452],{"id":453,"sortIndex":19,"researcher":18,"roles":454,"affiliations":455,"properties":456},"1e1faed0-ed01-4ece-9a19-c505e99aa798",[],[],{"openalex":457,"title":459},{"VOID":458},"A5053798294",{"EN":460},"P. L. B. Bruijnzeel",{"url":18,"publisher":462,"properties":18},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":463,"slug":10,"properties":464,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":467,"manageAffiliations":468,"indexDatabases":469,"url":18,"thumbnailPath":18,"statistic":470,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":465,"title":466},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":471,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":472,"totalCitation":38,"totalCitationByYear":473,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":474,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"total":19,"publishYear":18,"statisticByYear":476},{},"2009-07-01",[479,483],{"id":18,"text":480,"url":18,"identifiers":481},"Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, Macleod WB et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomized equivalence trial. Lancet 2008;371:49-56.",{"doi":482},"10.1016\u002FS0140-6736(08)60071-9",{"id":18,"text":484,"url":18,"identifiers":485},"Arifeen SE, Baqui AH. Treating sever pneumonia in children: we can do better. Lancet 2008;371:7-8.",{"doi":486},"10.1016\u002FS0140-6736(08)60045-8",{"id":488,"createTime":489,"updateTime":490,"relativeEntities":491,"slug":492,"properties":493,"entityType":72,"verifyStatus":17,"verifyTime":490,"verifyNote":73,"syncStatus":17,"languages":504,"translateLanguages":18,"viewCount":19,"primaryUrl":505,"fullTextUrl":18,"authors":506,"publicationType":87,"publisherRelationship":516,"citationCount":19,"citationInfo":536,"publishDate":538,"publishYear":112,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":539,"isForceReanalyzing":118},"d21a9166-6668-4bb8-b382-f5f7d50ee5a1","2024-04-18T21:34:43.454+00:00","2025-02-23T23:51:09.124+00:00",[],"Protonpompremmers-vertragen-de-eliminatie-uit-plasma-van-methotrexaat-bij-hoge-doseringen",{"mag":494,"keywords":496,"openalex":497,"abstract":499,"title":500,"doi":502},{"VOID":495},"2154031137",{},{"VOID":498},"W2154031137",{},{"NL":501},"Protonpompremmers vertragen de eliminatie uit plasma van methotrexaat bij hoge doseringen",{"VOID":503},"10.1007\u002Fbf03079977",[75],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002FBF03079977",[507],{"id":508,"sortIndex":19,"researcher":18,"roles":509,"affiliations":510,"properties":511},"29c229e4-58e7-424c-8fc8-e77ea9937f49",[],[],{"openalex":512,"title":514},{"VOID":513},"A5037078769",{"EN":515},"H. J. M. G. Nelissen‐Vrancken",{"url":18,"publisher":517,"properties":530},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":518,"slug":10,"properties":519,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":522,"manageAffiliations":523,"indexDatabases":524,"url":18,"thumbnailPath":18,"statistic":525,"gsStatistic":18,"type":50,"analyzePriority":18},[],{"issn":520,"title":521},{"VOID":13},{"VOID":15},[],[],[],{"impactFactor":19,"impactFactorByYear":526,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":25,"totalPublicationByYear":527,"totalCitation":38,"totalCitationByYear":528,"totalCitationPerPublication":45,"totalCitationPerPublicationByYear":529,"hindexLast5Year":40,"hindex":40},{},{"1997":27,"1998":28,"1999":29,"2000":30,"2001":31,"2002":32,"2003":33,"2004":34,"2005":35,"2006":29,"2007":36,"2008":36,"2009":37},{"1998":40,"1999":41,"2000":42,"2003":43,"2004":42,"2007":44,"2008":44},{"1998":47,"1999":47,"2000":48,"2003":49,"2004":45,"2007":45,"2008":45},{"volume":531,"pages":532,"issue":534},{"VOID":104},{"VOID":533},"99-100",{"VOID":535},"6",{"total":19,"publishYear":18,"statisticByYear":537},{},"2009-06-01",[540],{"id":18,"text":541,"url":18,"identifiers":542},"Suzuki K, Doki K, Homma M et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2008;67:44-9.",{"doi":543},"10.1111\u002Fj.1365-2125.2008.03303.x"]